Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report sent to investors on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ MRNS opened at $0.55 on Friday. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $1.97. The firm has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The business has a fifty day simple moving average of $0.55 and a 200 day simple moving average of $0.58.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals during the third quarter worth about $104,000. Virtu Financial LLC acquired a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at approximately $54,000. JPMorgan Chase & Co. lifted its position in shares of Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares in the last quarter. Finally, Deltec Asset Management LLC acquired a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth about $107,000. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.